1. Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes;Nigro;Ann Pharmacother,2013
2. Invokana (canagliflozin) [Package insert],2013
3. US Food and Drug Administration. FDA approves Invokana to treat type 2 diabetes. March 29, 2013. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm. Accessed October 3, 2013.
4. The sodium/glucose cotransport family SLC5;Wright;Eur J Physiol,2004
5. Renal N+-glucose transporters;Wright;Am J Physiol Renal Physiol,2001